Gamma Knife Surgery for Intracranial Lesions

Definition and Technology

Gamma Knife is a specialized device developed in 1951 by Leksell at the Karolinska Institute in Stockholm, Sweden, consisting of approximately 200 cobalt-60 sources arranged in a helmet-like configuration that produce gamma rays with an average energy of 1.25 MeV 1, 2
Gamma Knife surgery uses a stereotactic fixation system and noncoplanar convergent beams that create a very sharp peripheral dose fall-off at the target edge 1
Linear accelerator (LINAC)-based systems can also deliver stereotactic radiosurgery, with the gantry moving in space to change the delivery angle 1
CyberKnife is a specific type of LINAC-based system that delivers similar submillimeter accuracy without requiring a stereotactic frame, using an image guidance system with kilovolt images before each beam delivery 1
No platform has demonstrated superiority over another; the primary factor in successful SRS is correct application by treating physicians 1

Treatment of vestibular schwannomas (acoustic neuromas) 3
Management of paragangliomas with tumor control rates of 88-100% 4
Complete pain relief is initially achieved in approximately 75% of trigeminal neuralgia patients, with about 50% maintaining this outcome at three years 5
Pain relief typically occurs within three months after treatment 5
Results are better when used as primary treatment in patients with typical trigeminal neuralgia symptoms 5
A minimum radiosurgical dose of 70 Gy delivered to a 4 mm target at the sensory root of the trigeminal nerve is recommended 6

Requires a short hospital stay compared to traditional neurosurgical procedures 6
Provides immediate relief of pain in most patients with trigeminal neuralgia 6
Lower risk of complications compared to open surgical procedures 3
Most effective for smaller tumors (maximum diameter <3 cm) 7, 4
Current data on effectiveness are largely observational with generally poor quality reporting 6, 5

For small to medium-sized tumors (<3 cm diameter), Gamma Knife is particularly effective for single-fraction treatment, according to the American Academy of Neurology 8, 9
For larger tumors (>3 cm diameter), hypofractionated stereotactic radiotherapy using LINAC-based systems like TrueBeam is generally preferred, as recommended by the American Society for Radiation Oncology 8, 9
The American Association of Neurological Surgeons suggests that for tumors causing mass effect on the brainstem, there is no clear definition by diameter or volume alone for the upper limit of radiosurgery 8
The National Comprehensive Cancer Network recommends stereotactic radiosurgery (SRS) as primary or complementary treatment for surgical resection of paragangliomas, with Gamma Knife radiosurgery showing volumetric tumor control and clinical control in 94.8% and 91.4% of cases, respectively 9, 10
The Endocrine Society suggests that radiotherapy options include stereotactic radiotherapy, fractionated proton beam, and gamma knife approaches for persistent or recurrent Cushing's disease not amenable to curative surgery, with a total radiation dose of 45 Gy in 25 fractions over 35 days being effective 11

A meta-analysis examining radiosurgical treatment showed that Gamma Knife, LINAC, and CyberKnife technologies all exhibited similarly high rates of tumor control (95%) and clinical control (97%) across all studies, according to the American College of Radiology 9
The American Heart Association notes that complication rates are likely to decrease as institutional experience matures, with both modalities being generally safe with low complication rates 9